



ARK
SURGICAL

PEACE OF MIND FOR GYN SURGERY


Simple and safe laparoscopic surgery



Unmet Need



42% of women will have a hysterectomy by age 85,
(600K cases yearly in the U.S.)



In 2014 the FDA warned against **cancerous tissue dispersion** during **laparoscopic hysterectomy**




The FDA is calling companies to develop tissue containment systems to allow safe laparoscopic procedures

After the FDA warning, surgeons compromise with alternative methods that are more **difficult, lengthy, risky and costly!**



UPDATE: The FDA recommends performing contained morcellation in women when laparoscopic power morcellation is appropriate



Enabling
Simple & Safe


Laparoscopic
GYN Surgery

Press to view
animation



LapBox Safety Features

Double wall provides
double safety



1

2



Healthy organs kept
far from chamber

Shorter procedures



3

LapBox™ Key Advantages

- 01 Double wall for enhanced safety
- 02 Surrounding organs kept far from morcellation chamber
- 03 Easy and fast set up and use
- 04 Short learning curve (designed for the majority of surgeons*)
- 05 Supports both power and manual morcellation



LapBox is a safe, user-friendly solution for organ removal

*80% of hysterectomies are performed by surgeons who perform 1-2 hysterectomies per month.


Hysterectomy Treatment Alternatives



Laparoscopic
39%

Vaginal Hysterectomy

- Requires high level surgeons
- Suitable only for limited number of patients



Abdominal
48%

Abdominal Hysterectomy

- Requires 5-7" incision
- Results in more pain
- Larger scar
- Highest complication rate
- Readmissions
- Death

Vaginal
13%

Competitor Landscape

	Enhanced Safety	Power Morcellation	Manual Morcellation	User Friendly	Time Saving	Regulatory Status
LapBox (Ark Surgical)	✓	✓	✓	✓	✓	FDA Expected 2021
PneumoLiner (Olympus)	X	✓	X	X	X	FDA approved
Alexis (Applied Medical)	X	X	✓	X	X	FDA approved
More-Cell-Safe/ MorSafe / Others	X	✓	X	X	X	CE mark

Supportive Surgeon Feedback

I like the ring concept - keeps the opening open...[and] that LapBox keeps the other organs away from the procedure and doesn't stick to uterus so no danger to the bag.

U.S. GYN Surgeon, Yale Medical Center

As I am a laparoscopic surgeon I'm always on the lookout for new ways to extract tumors... Most institutions have gotten away from power morcellation so I find LapBox intriguing.

U.S. GYN Surgeon, New Jersey



I really liked the simplicity of your approach...The U.S. docs are desperate for a pragmatic solution!

European OB/GYN Department Head, Academic Medical Center

I do a lot of hysterectomies in large uterus that removing the specimen takes a long time and I am happy to see this box might be helpful.

U.S. GYN Surgeon, Yale Medical Center

If we had [LapBox] we would definitely go back to lap surgery using power morcellation... would even use it with suspected cancer and suspicious masses.

U.S. GYN Surgeon, Connecticut

Economic Drivers

LapBox addresses a global potential market of
~1.5M procedures and \$750M annually



Replacing open
surgeries with
laparoscopic procedure



savings > \$2,000
when converting inpatient
to outpatient setting


Perform
laparoscopic procedures
faster and safer




- Reducing operation time
- Procedures meet FDA's recommendations

Additional Indications


LapBox will address additional procedures: **Myomectomy, Cystectomy, Salpingo-Oophorectomy** and non-GYN procedures: **Nephrectomy, Splenectomy**.




Splenectomy




Cystectomy
(Cyst removal)



Myomectomy
(Fibroid removal)



Salpingo-Oophorectomy
(Ovaries and Fallopian
Tube removal)



Nephrectomy

Marketing Strategy

STAGE 1

Soft launch focused on 3-5 leading hospitals and KOLs in the U.S.



STAGE 2

Collaborations with leading companies in the field of women's health / laparoscopic instruments

Market Players and Target Buyers



Ark Surgical offers a superior, complementary product
and is a prime candidate for acquisition post FDA clearance



Medical device companies
focused on women's health:




Medical device companies in
the laparoscopic field:



Power morcellator
companies:



Value to Strategic Partners



50% of the global population as target customers



Women's health is a fast growing market segment – with hysterectomy a high profile clinical need



Answers a specific FDA call for a new Femtech device



Clear cut safety advantages with short learning curve - facilitating a fast adoption rate

Road Map - Achievements and Milestones

<2020



2021



2022

First in Human
clinical study has
started and
expected to be
completed
by **end of 2020**



FDA clearance
planned for Q2 2021.
510k status
approved with
no clinical data
required);
CE Mark during 2021



Initial US
pilot release
in Q4 2021 to
generate data,
build exposure
and demonstrate
utilization



Marketing
agreement
in 2022
leading to sales
and
a cash flow
positive position




Investment Roadmap



Use of Proceeds

The \$1.5M investment will be used to implement the go-to-market plan over a 2-year period

	Stage 1 - 2020	Stage 2 - 2021
Production and Inventory	200,000	100,000
Transfer to production - NRE		
Units for FDA testing		
Units for post marketing use		
R&D	125,000	100,000
Gen. 2 development		
Gen 2. testing		
Marketing	50,000	450,000
US pilot release		
Post marketing studies		
Regulatory	75,000	50,000
CE clearance		
Gen. 2 FDA submission		
G&A	150,000	200,000
IP management		
Infrastructure		
Total	\$600,000	\$900,000



Sales and Revenue Projection

	2022	2023	2024	2025	2026
Units	6,000	30,000	96,000	120,000	144,000
Revenues	\$1,500,000	\$7,500,000	\$24,000,000	\$27,000,000	\$33,120,000
COGS	\$600,000	\$2,400,000	\$4,800,000	\$6,000,000	\$7,200,000
Gross profit	\$900,000	\$5,100,000	\$19,200,000	\$21,600,000	\$25,920,000

From 2022 sales **via marketing partner** –
transfer price - \$250;
COGS - <\$50

Assumes partner achieving
12% market penetration by
Y5 **for hysterectomy
procedures only**

Doesn't include sales for
myomectomy,
cystectomy, splenectomy,
nephrectomy

Investment Opportunity

Total investment sought	➤ \$1.5M at a \$3.4M pre-money valuation
Option to invest in two tranches	➤ First tranche of \$600K and second \$900K following receipt of FDA clearance
Substantial increase in value expected:	➤ <ul style="list-style-type: none">• FIH study completion• FDA clearance• Initial commercial utilization• Marketing agreement
Potential ROI	➤ ~5X within 2 years

Management & Medical Advisory Board



ZOHAR GENDLER
Chairman

Led the establishment and investment in more than 50 companies such as Prolor Biotech (sold to OPKO for \$480M, NYSE: OPK), Mazor (sold to Medtronic for \$1.6B), ReWalk (NASDAQ: RWLK), Corindus (sold to Siemens Healthineers for \$1.1B), and many others.



STAV TORI
CEO

Experienced medical device professional with 10 years' experience in developing, manufacturing and clinical testing of medical implants and devices for several biomedical companies such as Carbo-Fix Orthopedics, NMB Medical and Disc-O-Tech.



DR. ABRAHAM YAARI
Co-founder & Medical Director

Graduated in 1990 from the Hebrew University, Jerusalem, Specialized in Obstetrics and Gynecology in New York and then practiced in Connecticut. Experienced laparoscopic surgeon. Currently affiliated Saint Mary's Hospital in Connecticut.



AARON FELDMAN
Co-founder & Director of Business Development

Seasoned medical device entrepreneur and manager. Served as CEO of Rafael Medical Technologies and CardioFlow. Currently director of business development of MST and co-founder of Restore Medical (Incentive incubator) and FetalEase.



Hugh S. Taylor, MD

Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology; Chair of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine; Chief of Obstetrics and Gynecology, Yale-New Haven Hospital.



Prof. Moti Goldenberg, MD

Head of the Gynecological Department at Sheba Medical Center. Head consultant at Assuta Medical Center and Associate Professor at the Sackler School of Medicine. Member of the ESGE, AAGL, the Israeli Endoscopic Society and the IRCAD International advisory board.



Yuval Kaufman, MD

Senior Consultant at the Department of Obstetrics & Gynecology at Carmel Medical Center in Haifa, Israel and at Assuta Private Hospital in Haifa, Israel. He is a Cum Laude Alumni of the Technion Israeli Institute for Technology.



Prof. Michael Stark

Leading European GYN surgeon and consultant to companies in the medical device field including surgical robotics. Adjunct professor at the Moscow Institute of Physics and Technology. Currently serves as President of NESA, the New European Surgical Academy



ARK
SURGICAL

Thank You.

Join us in improving treatment for
millions of women undergoing
gynecological surgery.

